NCT06255977View on ClinicalTrials.gov

A Study Evaluating the Safety and Efficacy of Neuroprotective Peptide CN-105 Peptide in Patients With Acute Supratentorial Intracerebral Hemorrhage

PHASE2RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

August 24, 2022

Primary Completion Date

May 31, 2024

Study Completion Date

August 31, 2024

Conditions
Intracerebral Hemorrhage
Interventions
DRUG

CN-105

Injection every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of CN-105 will be administered as a slow IV bolus over 30 minutes.

Trial Locations (1)

Unknown

RECRUITING

Beijing Tiantan Hospital, Beijing

All Listed Sponsors
collaborator

SDM Bio Service Inc.

UNKNOWN

lead

Beijing Tiantan Hospital

OTHER